<unk>  (3,7-dicyclopropylmethyl-9,9-tetramethylene-3,7-diazabicyclo-3,3,1-nonane) is an experimental class III antiarrhythmic agent currently being investigated for the treatment of atrial fibrillation.<unk>  blocks multiple types of potassium channels in the heart resulting in slowed heart rate. While the effects of<unk>  have been demonstrated in both atrial and ventricular muscle, repolarization is prolonged more efficiently in the atria.<unk>  is administered intravenously and has a half-life of approximately 8 –13 hours in circulation.<unk>  is being developed as an alternative to other antiarrhythmics as incidence of additional arrhythmic events is lower compared to other class III agents.<unk>  also has significant anti-ischemic properties and was initially investigated as a potential treatment for angina until its antiarrhythmic effects were discovered.<unk>  is manufactured by Solvay Pharmaceuticals Inc. under the proposed trade name Pulzium and is currently in phase III of clinical testing for atrial fibrillation.
Tedisamil
Metipranolol
Xipamide
Thiram
Mexiletine
Bupranolol
Propranolol 
Etafenone